Curative Biotechnology, Inc. Announces Trading Symbol Change to “CUBT”
29. April 2021 10:12 ET
|
Curative Biotechnology, Inc.
Kapil Bharti, Ph.D. and Dimiter Dimitrov, Ph.D. Join Scientific and Clinical Advisory Board Boca Raton, FL, April 29, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) a...
Connectyx Reports Fiscal Year 2020 Financial Results
09. März 2021 10:24 ET
|
Connectyx Technologies Holdings Group, Inc
Biotechnology Company Issues Highlights and Subsequent Events Boca Raton, Fla, March 09, 2021 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the...
Connectyx Announces Key Biotech Industry Veterans to Management Team
11. Februar 2021 10:50 ET
|
Connectyx Technologies Holdings Group, Inc
Expertise in Clinical Development, Regulatory Affairs and Manufacturing Represented Boca Raton, Fla, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX)...
Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease
04. Februar 2021 11:17 ET
|
Connectyx Technologies Holdings Group, Inc
Boca Raton, FL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel...
Connectyx Announces Name Change to Curative Biotechnology and Secures Bridge Financing
23. November 2020 10:00 ET
|
Connectyx Technologies Holdings Group, Inc
Initial Biotechnology Portfolio Includes Therapies for Glioblastoma and Late Stage Rabies Boca Raton, FL, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX)...
Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat Glioblastoma
16. Oktober 2020 11:00 ET
|
Connectyx Technologies Holdings Group, Inc
Boca Raton, FL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel...
Connectyx Technologies Holdings Group, Inc. Announces Definitive Agreement with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies
09. Oktober 2020 09:30 ET
|
Connectyx Technologies Holdings Group, Inc
Boca Raton, FL, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel...
Connectyx Technologies Holdings Group, Inc. Announces Strategic Relationship with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies
27. August 2020 09:30 ET
|
Connectyx Technologies Holdings Group, Inc
Company to Acquire Worldwide Rights for Development of IMT504 Boca Raton, FL, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the...
Connectyx in Licensing Discussions for Novel Monoclonal Antibody to Treat Pediatric Glioblastoma
06. Juli 2020 09:30 ET
|
Connectyx Technologies Holdings Group, Inc
Boca Raton, FL, July 06, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel...
Connectyx Welcomes I. Richard Garr, Esq. to Company’s Scientific Advisory Board
19. Mai 2020 09:30 ET
|
Connectyx Technologies Holdings Group, Inc
Company Reports First Quarter Results Boca Raton, FL, May 19, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development stage...